A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc.
A new therapy developed by researchers at Rush University Medical Center is showing success as a way to prevent COVID-19 symptoms in mice.
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
Article title: Oxytocin’s anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach Authors: Ali S. Imami, Sinead M. O’Donovan, Justin F. Creeden, Xiaojun Wu, Hunter Eby, Cheryl B. McCullumsmith, Kerstin Uvnäs-Moberg, Robert E. McCullumsmith, Elissar Andari From the authors: “Understanding the…
Surgeons at University Hospitals Cleveland Medical Center have improved the prognosis of several cardiac patients after emergency FDA approval of a diaphragm pacing device.
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
For the first time, surgeons at Northwestern Medicine performed a double-lung transplant on a patient whose lungs were damaged by COVID-19. The patient, a Hispanic woman in her 20s, spent six weeks in the COVID ICU on a ventilator and extracorporeal membrane oxygenation (ECMO), a life support machine that does the work of the heart and lungs.
The Society for Risk Analysis (SRA), the world’s leading authority on risk sciences and its applications, is hosting a webinar on Thursday, June 11 at 11 a.m. ET to discuss the latest research on aerosol transmission of COVID-19.
As a leading New Jersey academic medical center and member of Hackensack Meridian Health, Jersey Shore University Medical Center is able to provide its patients access to existing clinical trials and the latest medical techniques in a variety of specialties. Currently, the medical center is recruiting individuals who have been clinically diagnosed with COVID-19 or have laboratory test results showing they have COVID-19 antibodies to donate their blood and potentially assist patients in their recovery from the virus.